Pembrolizumab Treatment-Induced Liver Toxicity
Abstract T cells play a critical role in immune responses against neoplasm. This finding contributed to the immunotherapy development, an effective treatment for many cancers nowadays. Programmed cell death protein 1 (PD1) is an inhibitory receptor on T cells which downregulate T-cell function per l...
Gespeichert in:
| Veröffentlicht in: | Case Reports in Gastroenterology 2021-05, Vol.15 (2), p.742-750 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 750 |
|---|---|
| container_issue | 2 |
| container_start_page | 742 |
| container_title | Case Reports in Gastroenterology |
| container_volume | 15 |
| creator | Calderon, Benoît Stancu, Alma Vanel, François-Roger Vazquez, Léa |
| description | Abstract
T cells play a critical role in immune responses against neoplasm. This finding contributed to the immunotherapy development, an effective treatment for many cancers nowadays. Programmed cell death protein 1 (PD1) is an inhibitory receptor on T cells which downregulate T-cell function per ligation with its ligands (PDL1 and PDL2). PD1 blockade is used to enhance antitumor immunity. Pembrolizumab is a humanized monoclonal anti-PD1 antibody currently used in the management of melanoma, non-small-cell lung cancer, and Hodgkin lymphoma. Most of the treatment toxicities are immune-related adverse events, but grade 3–4 toxicities occur in up to 5% of patients, mainly dermatologic. We present a case of grade 4 pembrolizumab-induced liver toxicity associated with an excellent treatment response in a Caucasian woman. |
| doi_str_mv | 10.1159/000518128 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmed_primary_34594175</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A674781606</galeid><doaj_id>oai_doaj_org_article_6824839258874d3cbf6831f21c643224</doaj_id><sourcerecordid>A674781606</sourcerecordid><originalsourceid>FETCH-LOGICAL-c557t-f774766baff231533793e782f30bcf4c3d9af54386843bc03bf91e795a30ec543</originalsourceid><addsrcrecordid>eNpdkstv1DAQhy1ERduFA3eEVuqlHLL4bedSqap4rLQSHJaz5TjjxUsSFyepWv56HLKs2soHWzPf_ObhQegtwStCRPkRYyyIJlS_QGdESlpgycjLR-9TdN73e4wlp4y8QqeMi5ITJc7Q6ju0VYpN-DO2tlpuE9ihhW4o1l09OqiXm3AHabmN98GF4eE1OvG26eHN4V6gH58_bW--FptvX9Y315vCCaGGwivFlZSV9T4nFIypkoHS1DNcOc8dq0vrBWdaas4qh1nlSwKqFJZhcNmxQOtZt452b25TaG16MNEG888Q087YNATXgJGacs1KKrRWvGau8lIz4ilxkjNKJ62rWet2rFqoXe4u2eaJ6FNPF36aXbwzuTY5TWyBLg8CKf4eoR9MG3oHTWM7iGNvqFBayanjjF48Q_dxTF0e1URhnhW1ztRqpnY2NxA6H3Nel08NbXCxAx-y_XqS1ETiSfbDHOBS7PsE_lg9wWZaAXNcgcy-f9zukfz_5xl4NwO_bNpBOgKH-L9a2bFP</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2570443688</pqid></control><display><type>article</type><title>Pembrolizumab Treatment-Induced Liver Toxicity</title><source>DOAJ Directory of Open Access Journals</source><source>Karger Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Calderon, Benoît ; Stancu, Alma ; Vanel, François-Roger ; Vazquez, Léa</creator><creatorcontrib>Calderon, Benoît ; Stancu, Alma ; Vanel, François-Roger ; Vazquez, Léa</creatorcontrib><description>Abstract
T cells play a critical role in immune responses against neoplasm. This finding contributed to the immunotherapy development, an effective treatment for many cancers nowadays. Programmed cell death protein 1 (PD1) is an inhibitory receptor on T cells which downregulate T-cell function per ligation with its ligands (PDL1 and PDL2). PD1 blockade is used to enhance antitumor immunity. Pembrolizumab is a humanized monoclonal anti-PD1 antibody currently used in the management of melanoma, non-small-cell lung cancer, and Hodgkin lymphoma. Most of the treatment toxicities are immune-related adverse events, but grade 3–4 toxicities occur in up to 5% of patients, mainly dermatologic. We present a case of grade 4 pembrolizumab-induced liver toxicity associated with an excellent treatment response in a Caucasian woman.</description><identifier>ISSN: 1662-0631</identifier><identifier>EISSN: 1662-0631</identifier><identifier>DOI: 10.1159/000518128</identifier><identifier>PMID: 34594175</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Alcohol ; anti-programmed cell death protein 1 ; Antibodies ; Antigens ; Apoptosis ; Asymptomatic ; Biopsy ; Cancer ; Care and treatment ; Case reports ; Cell death ; Complications and side effects ; Cytotoxicity ; Enteral nutrition ; Hepatitis ; Immune response ; immune-mediated hepatitis ; Immunotherapy ; Liver ; lung adenocarcinoma ; Lung cancer ; Lung cancer, Non-small cell ; Lymphatic system ; Metastasis ; Monoclonal antibodies ; Non-Hodgkin's lymphomas ; Nutrition ; Ostomy ; Patients ; pembrolizumab ; Proteins ; Radiation therapy ; Single Case ; Steroids ; T cells ; Targeted cancer therapy ; Thyroid gland ; Viral antibodies</subject><ispartof>Case Reports in Gastroenterology, 2021-05, Vol.15 (2), p.742-750</ispartof><rights>2021 The Author(s). Published by S. Karger AG, Basel</rights><rights>Copyright © 2021 by S. Karger AG, Basel.</rights><rights>COPYRIGHT 2021 S. Karger AG</rights><rights>2021 The Author(s). Published by S. Karger AG, Basel . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content</rights><rights>Copyright © 2021 by S. Karger AG, Basel 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c557t-f774766baff231533793e782f30bcf4c3d9af54386843bc03bf91e795a30ec543</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436642/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436642/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,27635,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34594175$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Calderon, Benoît</creatorcontrib><creatorcontrib>Stancu, Alma</creatorcontrib><creatorcontrib>Vanel, François-Roger</creatorcontrib><creatorcontrib>Vazquez, Léa</creatorcontrib><title>Pembrolizumab Treatment-Induced Liver Toxicity</title><title>Case Reports in Gastroenterology</title><addtitle>Case Rep Gastroenterol</addtitle><description>Abstract
T cells play a critical role in immune responses against neoplasm. This finding contributed to the immunotherapy development, an effective treatment for many cancers nowadays. Programmed cell death protein 1 (PD1) is an inhibitory receptor on T cells which downregulate T-cell function per ligation with its ligands (PDL1 and PDL2). PD1 blockade is used to enhance antitumor immunity. Pembrolizumab is a humanized monoclonal anti-PD1 antibody currently used in the management of melanoma, non-small-cell lung cancer, and Hodgkin lymphoma. Most of the treatment toxicities are immune-related adverse events, but grade 3–4 toxicities occur in up to 5% of patients, mainly dermatologic. We present a case of grade 4 pembrolizumab-induced liver toxicity associated with an excellent treatment response in a Caucasian woman.</description><subject>Alcohol</subject><subject>anti-programmed cell death protein 1</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Apoptosis</subject><subject>Asymptomatic</subject><subject>Biopsy</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Case reports</subject><subject>Cell death</subject><subject>Complications and side effects</subject><subject>Cytotoxicity</subject><subject>Enteral nutrition</subject><subject>Hepatitis</subject><subject>Immune response</subject><subject>immune-mediated hepatitis</subject><subject>Immunotherapy</subject><subject>Liver</subject><subject>lung adenocarcinoma</subject><subject>Lung cancer</subject><subject>Lung cancer, Non-small cell</subject><subject>Lymphatic system</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Non-Hodgkin's lymphomas</subject><subject>Nutrition</subject><subject>Ostomy</subject><subject>Patients</subject><subject>pembrolizumab</subject><subject>Proteins</subject><subject>Radiation therapy</subject><subject>Single Case</subject><subject>Steroids</subject><subject>T cells</subject><subject>Targeted cancer therapy</subject><subject>Thyroid gland</subject><subject>Viral antibodies</subject><issn>1662-0631</issn><issn>1662-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DOA</sourceid><recordid>eNpdkstv1DAQhy1ERduFA3eEVuqlHLL4bedSqap4rLQSHJaz5TjjxUsSFyepWv56HLKs2soHWzPf_ObhQegtwStCRPkRYyyIJlS_QGdESlpgycjLR-9TdN73e4wlp4y8QqeMi5ITJc7Q6ju0VYpN-DO2tlpuE9ihhW4o1l09OqiXm3AHabmN98GF4eE1OvG26eHN4V6gH58_bW--FptvX9Y315vCCaGGwivFlZSV9T4nFIypkoHS1DNcOc8dq0vrBWdaas4qh1nlSwKqFJZhcNmxQOtZt452b25TaG16MNEG888Q087YNATXgJGacs1KKrRWvGau8lIz4ilxkjNKJ62rWet2rFqoXe4u2eaJ6FNPF36aXbwzuTY5TWyBLg8CKf4eoR9MG3oHTWM7iGNvqFBayanjjF48Q_dxTF0e1URhnhW1ztRqpnY2NxA6H3Nel08NbXCxAx-y_XqS1ETiSfbDHOBS7PsE_lg9wWZaAXNcgcy-f9zukfz_5xl4NwO_bNpBOgKH-L9a2bFP</recordid><startdate>202105</startdate><enddate>202105</enddate><creator>Calderon, Benoît</creator><creator>Stancu, Alma</creator><creator>Vanel, François-Roger</creator><creator>Vazquez, Léa</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>202105</creationdate><title>Pembrolizumab Treatment-Induced Liver Toxicity</title><author>Calderon, Benoît ; Stancu, Alma ; Vanel, François-Roger ; Vazquez, Léa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c557t-f774766baff231533793e782f30bcf4c3d9af54386843bc03bf91e795a30ec543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alcohol</topic><topic>anti-programmed cell death protein 1</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Apoptosis</topic><topic>Asymptomatic</topic><topic>Biopsy</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Case reports</topic><topic>Cell death</topic><topic>Complications and side effects</topic><topic>Cytotoxicity</topic><topic>Enteral nutrition</topic><topic>Hepatitis</topic><topic>Immune response</topic><topic>immune-mediated hepatitis</topic><topic>Immunotherapy</topic><topic>Liver</topic><topic>lung adenocarcinoma</topic><topic>Lung cancer</topic><topic>Lung cancer, Non-small cell</topic><topic>Lymphatic system</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Non-Hodgkin's lymphomas</topic><topic>Nutrition</topic><topic>Ostomy</topic><topic>Patients</topic><topic>pembrolizumab</topic><topic>Proteins</topic><topic>Radiation therapy</topic><topic>Single Case</topic><topic>Steroids</topic><topic>T cells</topic><topic>Targeted cancer therapy</topic><topic>Thyroid gland</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Calderon, Benoît</creatorcontrib><creatorcontrib>Stancu, Alma</creatorcontrib><creatorcontrib>Vanel, François-Roger</creatorcontrib><creatorcontrib>Vazquez, Léa</creatorcontrib><collection>Karger Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Case Reports in Gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Calderon, Benoît</au><au>Stancu, Alma</au><au>Vanel, François-Roger</au><au>Vazquez, Léa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pembrolizumab Treatment-Induced Liver Toxicity</atitle><jtitle>Case Reports in Gastroenterology</jtitle><addtitle>Case Rep Gastroenterol</addtitle><date>2021-05</date><risdate>2021</risdate><volume>15</volume><issue>2</issue><spage>742</spage><epage>750</epage><pages>742-750</pages><issn>1662-0631</issn><eissn>1662-0631</eissn><abstract>Abstract
T cells play a critical role in immune responses against neoplasm. This finding contributed to the immunotherapy development, an effective treatment for many cancers nowadays. Programmed cell death protein 1 (PD1) is an inhibitory receptor on T cells which downregulate T-cell function per ligation with its ligands (PDL1 and PDL2). PD1 blockade is used to enhance antitumor immunity. Pembrolizumab is a humanized monoclonal anti-PD1 antibody currently used in the management of melanoma, non-small-cell lung cancer, and Hodgkin lymphoma. Most of the treatment toxicities are immune-related adverse events, but grade 3–4 toxicities occur in up to 5% of patients, mainly dermatologic. We present a case of grade 4 pembrolizumab-induced liver toxicity associated with an excellent treatment response in a Caucasian woman.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>34594175</pmid><doi>10.1159/000518128</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1662-0631 |
| ispartof | Case Reports in Gastroenterology, 2021-05, Vol.15 (2), p.742-750 |
| issn | 1662-0631 1662-0631 |
| language | eng |
| recordid | cdi_pubmed_primary_34594175 |
| source | DOAJ Directory of Open Access Journals; Karger Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Alcohol anti-programmed cell death protein 1 Antibodies Antigens Apoptosis Asymptomatic Biopsy Cancer Care and treatment Case reports Cell death Complications and side effects Cytotoxicity Enteral nutrition Hepatitis Immune response immune-mediated hepatitis Immunotherapy Liver lung adenocarcinoma Lung cancer Lung cancer, Non-small cell Lymphatic system Metastasis Monoclonal antibodies Non-Hodgkin's lymphomas Nutrition Ostomy Patients pembrolizumab Proteins Radiation therapy Single Case Steroids T cells Targeted cancer therapy Thyroid gland Viral antibodies |
| title | Pembrolizumab Treatment-Induced Liver Toxicity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T19%3A34%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pembrolizumab%20Treatment-Induced%20Liver%20Toxicity&rft.jtitle=Case%20Reports%20in%20Gastroenterology&rft.au=Calderon,%20Beno%C3%AEt&rft.date=2021-05&rft.volume=15&rft.issue=2&rft.spage=742&rft.epage=750&rft.pages=742-750&rft.issn=1662-0631&rft.eissn=1662-0631&rft_id=info:doi/10.1159/000518128&rft_dat=%3Cgale_pubme%3EA674781606%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2570443688&rft_id=info:pmid/34594175&rft_galeid=A674781606&rft_doaj_id=oai_doaj_org_article_6824839258874d3cbf6831f21c643224&rfr_iscdi=true |